IDEAYA Biosciences, Inc. (IDYA)
Develops cancer drugs matched to patients' genetic profiles to improve treatment outcomes
$35.83-0.03%Healthcare
StockGlow Score
Bullish
BearishBullish
1 year ago+47.6%
The outlook
IDYA is trading above both its 50- and 200-day moving averages, positioning it in the upper portion of its 52-week range. Analyst consensus is strongly bullish with an average price target about 49% above the current level. The stock shows technical strength alongside broad analyst support.
What’s behind the score
Analyst consensusStrong Buy — 1.3 avg of 13 analysts
Price trendAbove its 50- & 200-day averages
52-week range74% of the way from its 52-week low to high
Price targetAvg target +49% vs current price
Analyst price target
~12-month · 13 analysts$53.54average target+49.4% vs now
Now $35.83
Low $37.00High $66.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$3.45B
52-wk high
$40.58
52-wk low
$22.09
50-day avg
$32.90
200-day avg
$32.55
Trailing P/E
—